Literature DB >> 12656434

Effect of methylprednisolone on coagulation.

H B Pandit1, C R Spillert.   

Abstract

This in vitro study examined the effects of methylprednisolone on coagulation status. Venous blood samples were collected from 12 adult subjects including healthy volunteers and patients presenting to the emergency department and analyzed for coagulation changes using the modified recalcification time (MRT) test prior to and after the addition of methylprednisolone. Mean +/- SD MRT control values before the addition of methylprednisolone (MRTC) and after (MRTCP) were 5.4 +/- 1.5 and 5.7 +/- 1.3 minutes, respectively. The MRT saline values prior to treatment with methylprednisolone (MRTS) and after (MRTSP) were 5.6 +/- 1.2 and 5.4 +/- 1.1 minutes, respectively. The MRT endotoxin prior to the introduction of steroid (MRTE) and after its addition (MRTEP) were 3.8 +/- 0.8 and 5.2 +/- 1.4 minutes, respectively. The MRTE values in the presence of methylprednisolone were significantly different between groups. This may suggest that the monocyte-stimulated release of the procoagulant tissue factor is inhibited by the corticosteroid, causing the blood to be relatively hypocoagulable.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 12656434      PMCID: PMC2608443     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  19 in total

1.  Effects of corticosteroids on coagulation of the blood.

Authors:  S OZSOYLU; H S STRAUSS; L K DIAMOND
Journal:  Nature       Date:  1962-09-22       Impact factor: 49.962

2.  The influence of ACTH and cortisone on certain factors of blood coagulation.

Authors:  R W SMITH; R R MARGULIS; M J BRENNAN; R W MONTO
Journal:  Science       Date:  1950-09-15       Impact factor: 47.728

3.  Is it time to change the prothrombin time?

Authors:  E J Lazaro; C R Spillert; R N Ponnudurai; K J Thayer
Journal:  Surgery       Date:  1995-11       Impact factor: 3.982

Review 4.  Clinical significance of increased thromboplastin activity on the monocyte surface--a brief review.

Authors:  T Lyberg
Journal:  Haemostasis       Date:  1984

5.  Tissue thromboplastin activity of isolated human monocytes.

Authors:  H Prydz; A C Allison
Journal:  Thromb Haemost       Date:  1978-06-30       Impact factor: 5.249

6.  Hypercoagulability in arterial disease.

Authors:  C R Spillert; V J Milazzo; W D Suval; E J Lazaro
Journal:  Angiology       Date:  1989-10       Impact factor: 3.619

7.  An assessment of monocyte procoagulant activity in patients with solid tumors.

Authors:  K S Dasmahapatra; N K Cheung; C Spillert; E Lazaro
Journal:  J Surg Res       Date:  1987-08       Impact factor: 2.192

8.  Shortened endotoxin-activated clotting times in patients with carcinoma.

Authors:  C R Spillert; E J Lazaro
Journal:  Am Surg       Date:  1987-03       Impact factor: 0.688

9.  Effect of corticosteroids on the human monocyte IgG and complement receptors.

Authors:  A D Schreiber; J Parsons; P McDermott; R A Cooper
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

10.  Modified recalcification time: a global coagulation screening test.

Authors:  C R Spillert; E J Lazaro
Journal:  J Natl Med Assoc       Date:  1993-08       Impact factor: 1.798

View more
  4 in total

Review 1.  Venous thrombosis and prothrombotic factors in inflammatory bowel disease.

Authors:  Fernando Magro; João-Bruno Soares; Dália Fernandes
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

2.  Efficacy of methylprednisolone pulse therapy in steroid-resistant nephrotic syndrome.

Authors:  Kazuetsu Mori; Masataka Honda; Masahiro Ikeda
Journal:  Pediatr Nephrol       Date:  2004-08-18       Impact factor: 3.714

Review 3.  Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.

Authors:  Johannes M M Boots; Maarten H L Christiaans; Johannes P van Hooff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 4.  Elevated risk of venous thromboembolic events in patients with inflammatory myopathies.

Authors:  Michał Nowak; Katarzyna Królak-Nowak; Aleksandra Sobolewska-Włodarczyk; Jakub Fichna; Marcin Włodarczyk
Journal:  Vasc Health Risk Manag       Date:  2016-06-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.